HRYZ Biotech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

A clinical-stage biotech developing next-generation antibody therapeutics for cancer and autoimmune diseases.

OncologyImmunology

A proprietary antibody discovery and engineering platform for developing monoclonal, bispecific, and conjugated antibodies with optimized properties.

Potential to out-license differentiated clinical-stage assets to global partners seeking innovation from China.

High burn rate and risk of clinical failure in a crowded therapeutic field with many similar candidates.

Faces intense competition from both large domestic pharma and numerous agile biotechs in the crowded Chinese antibody space.